| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Afatinib impurity 11 is associated with the same targets as its parent drug, Afatinib, which is the epidermal growth factor receptor (EGFR) family. This includes EGFRwt, EGFRL858R, EGFRL858R/T790M, and HER2. The impurity is classified as an EGFR inhibitor and is also linked to the autophagy pathway.
|
|---|---|
| ln Vitro |
As an impurity, Afatinib impurity 11 is not typically studied for its own biological activity. Its activity is inferred from its structural similarity to Afatinib, which inhibits EGFR family members with IC50s of 0.5 nM, 0.4 nM, 10 nM, and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M, and HER2, respectively.
|
| ln Vivo |
The in vivo activity of Afatinib impurity 11 is not typically studied as it is not a therapeutic agent. Its role is primarily as a reference standard for analytical purposes. The in vivo activity of the parent drug, Afatinib, is well-characterized as an orally bioavailable dual receptor tyrosine kinase inhibitor for the treatment of non-small cell lung carcinoma (NSCLC).
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed on Afatinib impurity 11 itself. However, the analytical methods used to detect and quantify this impurity may involve chromatographic techniques such as HPLC, which are validated to ensure the accurate measurement of impurity levels in Afatinib samples.
|
| Cell Assay |
In vitro cell-based assays are not performed on Afatinib impurity 11, as it is not a compound with intended biological activity. Instead, cell-based assays are used to characterize the activity of the parent drug, Afatinib, which is a potent inhibitor of EGFR signaling in various cancer cell lines.
|
| Animal Protocol |
In vivo animal experiments are not conducted with Afatinib impurity 11, as it is not a drug candidate for therapeutic use. The impurity is used for quality control and analytical testing purposes. Preclinical studies on the parent drug, Afatinib, have demonstrated its efficacy in animal models of cancer.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Afatinib impurity 11 is not available, as it is not a therapeutic agent. The pharmacokinetic properties of Afatinib, including its oral bioavailability and metabolic profile, have been extensively studied, as it is an approved drug. Afatinib impurity 11 is a controlled substance for research use only.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is reported for Afatinib impurity 11. The impurity is not used in vivo. The toxicity of the parent drug, Afatinib, is well-documented as part of its clinical safety profile. The presence of impurities is tightly controlled in pharmaceutical products to ensure safety.
|
| References |
Oncogene.2008 Aug 7;27(34):4702-11;Br J Cancer.2008 Jan 15;98(1):80-5.
|
| Additional Infomation |
Afatinib impurity 11 is a chemical reference standard used in the quality control of Afatinib, an FDA-approved anticancer drug. It is not a therapeutic agent and is not intended for human use. Its role is to ensure the purity and stability of Afatinib drug substance and products.
|
| Molecular Formula |
C21H18CLFN4O3
|
|---|---|
| Molecular Weight |
428.844027042389
|
| Exact Mass |
428.105
|
| CAS # |
1402086-20-7
|
| Related CAS # |
: 850140-72-6 (Afatinib free base); 850140-73-7 (Afatinib dimaleate)
|
| PubChem CID |
66555110
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
615
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=C(NC2=NC=NC3C=C(O[C@H]4CCOC4)C(=CC=32)NC(C=C)=O)C=CC(F)=C1Cl
|
| InChi Key |
MLHDLQIHGCIPJQ-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C21H18ClFN4O3/c1-2-20(28)27-18-8-14-17(9-19(18)30-13-5-6-29-10-13)24-11-25-21(14)26-12-3-4-16(23)15(22)7-12/h2-4,7-9,11,13H,1,5-6,10H2,(H,27,28)(H,24,25,26)/t13-/m0/s1
|
| Chemical Name |
N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~29.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 4.25 mg/mL (9.91 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 42.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (4.66 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3319 mL | 11.6594 mL | 23.3187 mL | |
| 5 mM | 0.4664 mL | 2.3319 mL | 4.6637 mL | |
| 10 mM | 0.2332 mL | 1.1659 mL | 2.3319 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
